We delivered an AI Medicare Advisor for a Summerville woman turning 65 with forty-seven pieces of mail on her kitchen table — one that separated the official notices from the advertising, ran her nine prescriptions against every Part D formulary sold in her county, made the Medigap underwriting deadline legible before she walked past it, and priced the three years of coverage her husband needed to bridge.

She turns 65 in November. The mail started in June. By the second week of August there were forty-seven separate pieces of it on the kitchen table in Summerville, and she had opened maybe a third, because the ones she opened all seemed to be telling her something different and none of them were from anybody she recognized. Two of the forty-seven were official.

One was the handbook from CMS. One was a notice from Social Security. The other forty-five were advertising, several of them designed to look like the two that were not. That is the first thing that went wrong, and it is not her fault.

The second thing is harder: Medicare is not one decision. It is four, they interact, two of them have deadlines that never reopen, and she was thirty days from one of them without knowing it existed. The AI Medicare Advisor read all forty-seven. It sorted them into what they actually were, explained what the two real notices required of her and when, and put the rest in a pile she could throw away without wondering.

Then it built the decision, in order. Part B first, because she is still working and covered through her employer. It confirmed she qualifies for a special enrollment period, which means no late penalty and no need to enroll in November at all — she had been told by a neighbor that she had to, and she does not. It set the window against her actual retirement date instead.

Part D was arithmetic nobody had done for her. She takes nine prescriptions. There are twenty-one standalone drug plans sold in Dorchester County, and the number people compare is the premium, which is the least important number. It took her nine drugs with dosages and ran each one against all twenty-one formularies — tier placement, quantity limits, prior authorization requirements, deductible treatment, and annual out-of-pocket at her actual fill schedule.

The plan with the lowest premium, which is the one she had nearly chosen from a television commercial, would have cost her $1,880 more over the year than the one that fit her list, because it put her rheumatoid arthritis medication on a tier it does not have to be on. Then the decision that has a door on it. Medigap versus Medicare Advantage is usually argued as a cost question, and it is not really. For six months after she starts Part B, South Carolina requires insurers to sell her a supplement regardless of her health.

After that window she can be medically underwritten, and she has a diagnosed autoimmune condition. It did not choose for her. It laid out plainly what each path costs now, what each path costs if her health changes, and that only one of the two paths is reversible — which is the fact the brochures leave out. It checked her three physicians and MUSC against every Advantage network in the county, because a plan is only as good as whether her rheumatologist is in it, and one of the two plans she was weighing had dropped the practice in January.

Her husband is 62 and covered under her employer plan, which ends when she retires. That is three years with no bridge. It priced marketplace coverage against her pension and his part-time income, showed where the subsidy falls away, and found that shifting a small amount of income timing kept them under the threshold. Last, it put the whole thing on a calendar — enrollment windows, the underwriting deadline, and a reminder every October, because formularies change every year and the plan that fits this year may not fit next year.

This is not a decision you make once. She chose a supplement and a standalone drug plan. Her specialist is covered, her infusion is covered, and her first-year cost came in $1,880 under the plan she almost bought from a commercial. "Forty-seven envelopes," she said, "and two of them were real.

Somebody should have told me that in June."